MTFB - Motif Bio plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1600
-0.0200 (-0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1800
Open2.2500
Bid2.1000 x 1200
Ask2.4600 x 3200
Day's Range2.1100 - 2.2500
52 Week Range1.5400 - 11.5000
Volume42,842
Avg. Volume746,072
Market Cap38.277M
Beta (3Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-1.4400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • Benzinga9 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • GlobeNewswire9 days ago

    Motif Bio Presents New Iclaprim Data at ECCMID 2019

    NEW YORK, April 16, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new.

  • GlobeNewswire10 days ago

    Motif Bio Reports Fiscal Year 2018 Results

    NEW YORK, April 15, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial.

  • PR Newswire13 days ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire21 days ago

    Motif Bio to Present Iclaprim Data at ECCMID 2019

    NEW YORK, April 04, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four.

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • GlobeNewswirelast month

    Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim

    NEW YORK, March 20, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the.

  • GlobeNewswirelast month

    Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board

    Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from the Board of Directors, effective immediately, to focus on other business commitments. Bruce Williams, a long-standing Board member, has been appointed Interim Chairman. Mr. Morgan has agreed to remain available to the Company in the coming months on an as needed basis to ensure a smooth transition.

  • Zacks Small Cap Research2 months ago

    MTFB: FDA Issues CRL for Iclaprim…

    By David Bautz, PhD NASDAQ:MTFB READ THE FULL MTFB RESEARCH REPORT Business Update CRL for Iclaprim On February 14, 2019, Motif Bio Plc (NASDAQ:MTFB) announced that the U.S. FDA issued a complete response ...

  • GlobeNewswire2 months ago

    Motif Bio Conference Call and Webcast

    NEW YORK, Feb. 19, 2019 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the.

  • GlobeNewswire2 months ago

    Motif BioSciences Enters into Amendment Agreement with Hercules Capital

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif BioSciences Inc. (a wholly owned subsidiary) has entered into an amendment agreement with its lender Hercules Capital, Inc (HTGC) (“Hercules”) in relation to the loan agreement as notified on 15 November 2017. Pursuant to the amendment, Motif BioSciences Inc. will make an immediate early repayment of $7 million and will make a further repayment of $0.5 million on the earlier of 90 days, being 18 May 2019, or receipt of funds from an equity raise of $2 million or greater. There will be a three-month interest-only period on the remaining loan, and Hercules has waived any applicable prepayment charges.  As a result, future interest and amortisation payments will be substantially lower than before.

  • GlobeNewswire2 months ago

    Motif Bio Receives Complete Response Letter from the FDA

    Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The CRL states that the FDA cannot approve the NDA in its present form and indicates that additional data are needed to further evaluate the risk for liver toxicity before the NDA may be approved. Motif Bio plans to request a meeting with the FDA as soon as possible to discuss potential options to address the deficiencies.

  • PR Newswire3 months ago

    Antimicrobials Working Group Announces Updates to Leadership Team

    WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...

  • GlobeNewswire6 months ago

    Motif Bio to participate at upcoming Jefferies London Healthcare Conference

    NEW YORK, Oct. 31, 2018 -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the.

  • Zacks Small Cap Research7 months ago

    MTFB: Additional Data for Iclaprim Presented at ESCMID/ASM…

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • Zacks Small Cap Research8 months ago

    MTFB: NDA for Iclaprim Accepted by FDA; PDUFA Date of Feb. 13, 2019…

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.